Akumin, a leading outpatient radiology and oncology service provider in the U.S., has partnered with Lunit to deploy their advanced AI-powered breast imaging technology that significantly enhances early breast detection capabilities across the United States.
By virtue of this partnership, Akumin will integrate the innovative AI solution known as Lunit INSIGHT DBT (Digital Breast Tomosynthesis) across its vast network of imaging centers to substantially augment the early detection of breast cancer nationwide.
The newly adopted AI technology is designed to enhance the accuracy, efficiency and confidence of breast cancer detection. INSIGHT DBT analyzes 2D and 3D digital breast tomosynthesis images to provide radiologists with automated abnormality scores and lesion localization that helps detect early-stage cancers more effectively.
This AI-powered solution has also received approval and clearance from the U.S. FDA (Food and Drug Administration), with clinical validation supported by over 100 peer-reviewed publications.
Dr. Nasir Siddiqui, Akumin’s Chief Medical Officer, emphasized the value of this partnership by stating that the AI solution meets their high standard of clinical excellence and will make a meaningful difference for patients.
“We are very excited to have an AI solution that meets our high standards of clinical excellence and that we believe will make a meaningful difference for the patients we serve, and the radiologists who care for them,” said Dr. Nasir Siddiqui. “Lunit stands out with strong clinical validation and proven real-world performance. Their technology reflects our commitment to innovation in care and ensures our patients benefit from the most advanced tools in early cancer detection.”
Akumin’s approach addresses industry-wide challenges such as the shortages of radiologists, rising capital expenditures, and the need to expand outpatient imaging access efficiently. By leveraging and deploying the INSIGHT DBT, Akumin will then offer healthcare systems a more scalable and economically viable alternative, ensuring that patients receive timely breast cancer screening services at accessible locations.
Brandon Suh, CEO of Lunit, highlighted the broader impact of this partnership by pointing out that when radiologists are equipped with best-in-class AI tools, patients benefit from earlier detection, better accuracy and improved general health outcomes.
“Akumin’s model is transforming how care is delivered across the U.S., and we’re proud to support that mission,” said Brandon Suh. “Akumin’s investment in Lunit INSIGHT DBT reflects a strategic, evidence-based approach to solving some of the most pressing challenges in diagnostic imaging.”
Lunit’s breast screening AI solutions will be adopted in over 200 imaging centers across the U.S. “It also builds on the growing momentum we’ve seen in the U.S. market, where Lunit’s breast screening AI is being implemented in over 200 imaging centers nationwide,” Suh said. “When radiologists are equipped with best-in-class AI, patients benefit from earlier detection, greater accuracy, and ultimately, better outcomes, when it matters most.”
The collaboration between Akumin and Lunit is an example of the transformative potential of AI in medicine and healthcare.
By combining Akumin’s extensive nationwide imaging network with Lunit’s cutting-edge AI-powered solutions, the partnership is set to elevate the early detection of breast cancer, improve operational efficiencies, as well as expand patient access to personalized and precision diagnostics.
